Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have received an average rating of “Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $12.67.

IMUX has been the subject of several research reports. D. Boral Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Immunic in a research report on Tuesday, January 7th. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, HC Wainwright started coverage on shares of Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price target for the company.

Insider Buying and Selling

In other Immunic news, Director Richard Alan Rudick bought 87,300 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the transaction, the director now directly owns 87,300 shares in the company, valued at $100,395. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after acquiring an additional 42,383 shares in the last quarter. Jane Street Group LLC lifted its position in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. Virtu Financial LLC bought a new position in Immunic during the 3rd quarter valued at $50,000. Finally, State Street Corp increased its position in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares during the period. Institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

NASDAQ:IMUX opened at $1.05 on Friday. The stock has a 50-day simple moving average of $1.13 and a 200 day simple moving average of $1.32. Immunic has a one year low of $0.97 and a one year high of $2.11. The company has a market capitalization of $94.58 million, a price-to-earnings ratio of -0.85 and a beta of 1.88.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.